Crossmark

Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors

Crossref DOI link: https://doi.org/10.1186/s40560-018-0303-y

Published Online: 2018-06-14

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tao, Jing http://orcid.org/0000-0001-9593-4305
Bukanova, Elena N.

Akhtar, Shamsuddin
License Information

Text and Data Mining valid from 2018-06-14
More Information

Article History

Received: 29 January 2018

Accepted: 31 May 2018

First Online: 14 June 2018

Ethics approval and consent to participate

: The authors confirm that any aspect of the work covered in this manuscript has been conducted with the ethical approval from Yale New Haven Hospital’s Institutional Review Board. Consent to participate was waived by the Institutional Review Board as data collection was retrospective with minimal risks to subjects.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.